Cutting Cost in Oncology: MD Anderson Tries Episode-Based Payments
This article was originally published in RPM Report
Executive Summary
At the Institute of Medicine’s National Cancer Policy Forum workshop, MD Anderson Cancer Center gave an update on its pilot to bundle payments using an episode-based model. The approach is less about the cost of drugs—and more about the overall cost of treatment.
You may also be interested in...
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.